Multiple myeloma is the second most common hematological malignancy character- Multiple myeloma is a heterogeneous disease with focal lesions in the BM but also elsewhere in the body; these lesions contain subclones that directly influence survival of patients as well as response to treatment.
| INTRODUCTION
Monoclonal gammopathies (MG), including multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS), are diseases characterized by malignant proliferation of clonal plasma cells in the bone marrow (BM). 1 Multiple myeloma is a heterogeneous disease with focal lesions in the BM but also elsewhere in the body; these lesions contain subclones that directly influence survival of patients as well as response to treatment. 1 Therefore, analysis of biopsy specimen obtained from a single site in the BM does not contain information about all pathological clones. 2 Liquid biopsies (biopsies of peripheral blood) represent a real promise for such diseases since circulating molecules detectable in peripheral blood (PB) mirror the complex heterogeneity of MG and can serve as potential diagnostic, prognostic, and predictive markers. We and others showed that these
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molecules include cell-free DNA 2, 3 and noncoding RNA (ncRNA), especially microRNA (miRNA) [4] [5] [6] and long noncoding RNA (lncRNA). 7 LncRNA expression is tissue specific and implicated in diverse biological functions. 8 LncRNA are involved not only in tumorigenesis but also in tumor progression and metastases. 9 These molecules also circulate in body fluids. 2, 7 This two-phased biomarker study focused on circulating lncRNA as potential diagnostic markers of MG.
| MATERIALS AND METHODS

| Patients and healthy donors
In total, 141 serum samples obtained from newly diagnosed MM patients (56 samples), MGUS patients (49 samples), and healthy donors (HD) (36 samples) were evaluated for this study (Table 1) . Multiple myeloma and MGUS patients were diagnosed according to the International Myeloma Working Group (IMWG) guidelines. 1 All patients' samples were collected at the time of diagnosis prior to treatment. Healthy donors' samples were age/sex matched to patients as described in Table 1 . All patients were diagnosed at the University Hospital Brno, Czech Republic, and signed the informed consent form approved by the Ethics committee of the hospital in accordance with the current version of the Helsinki Declaration.
| Sample preparation and exosome isolation
Serum samples were collected as previously described. 4 Serum exosomes were isolated by miRCURY Exosome Isolation Kit (Exiqon, Vedbaek, Denmark) according to manufacturer's protocol and characterized by transmission electron microscopy (negative dyeing, 2% ammonium molybdate). Exosomal fraction of serum was used for total RNA extraction as described below.
| Extraction of total RNA
Total RNA was extracted using miRNeasy Serum/Plasma Kit (Qiagen, Hilden, Germany) based on manufacturer's instructions. RNA quantity and purity was determined spectrophotometrically using NanoDrop ND-1000 Spectrophotometer (Thermo Scientific, Wilmington, Delaware).
| Screening phase of the study-lncRNA profiling
In total, 84 candidate lncRNA were determined by RT2 lncRNA PCR Array-Human lncRNA Finder (Qiagen, Germany) using exosomal fraction of serum of six MM patients and six HD in the screening part of the study according to manufacturer's instructions on 7500 Real-Time PCR System. Analysis of data was performed using SDS version 2.0.1 software (Applied Biosystem, USA). The relative expression levels of 
| Interphase fluorescence in situ hybridization analysis (I-FISH)
Interphase fluorescence in situ hybridization analysis was performed as described previously 11 and examined for presence of gain(1)(q21), del(13)(q14), del(17)(p13), t(4;14), and hyperdiploidy status of MM patients. Available I-FISH data are listed in Table 1 .
| Statistical evaluation
Expression data from lncRNA profiling were statistically evaluated in the environment of statistical language R by use of Bioconductor package and LIMMA approach. P values below 0.05 were considered as statistically significant. P values from profiling were adjusted according to Bonferroni correction for multiple comparisons.
Standard descriptive statistics were applied. Statistical significance of differences in continuous variables among groups of patients was analyzed using nonparametric Kruskal-Wallis or Mann-Whitney U test. For the robust analysis of continuous parameters relationship, the Spearman correlation coefficient was used.
Receiver operating characteristic (ROC) was used to determine sensitivity and specificity of each lncRNA or their combinations based on multivariate logistic regression model and area under the curve (AUC).
Survival rates were estimated using the Kaplan-Meier method. Univariate and multivariate Cox proportional hazards models were used to assess the association of prognostic factors with overall survival. The 3 | RESULTS
| Screening phase of the study-lncRNA profiling
In the screening phase of the study, we determined expression profiles of 84 lncRNA in serum exosomes of six MM patients vs six HD. We identified lncRNA PRINS as differentially expressed in MM patients (all adjusted P < 0.042) (Figure 1 ). We selected UCA1, NEAT1, LINC-ROR, and PRINS for further independent validation.
| Validation of candidate lncRNA by qPCR
We employed lncRNA specific assays (UCA1, NEAT1, LINC-ROR, and PRINS) on a larger cohort of 50 newly diagnosed MM patients, 49
newly diagnosed MGUS patients, and 30 HD to test candidate lncRNA expression in exosomal fraction of serum. Results confirmed FIGURE 1 Expression levels of circulating lncRNA PRINS in screening phase of the study. Expression levels of specific lncRNA PRINS (P < 0.042) in serum exosomes of six multiple myeloma (MM) patients and six healthy donors (HD) from the screening phase of the study were analyzed using nonparametric Mann-Whitney U test 
| Correlation of PRINS expression with biochemical parameters
In order to determine correlation of lncRNA expression levels with clinical parameters and infiltration of BMPCs, we performed Spearman bivariate correlation. In MM patients, expression levels of exosomal PRINS negatively correlated with BMPCs infiltration (r s = −0.422; P < 0.05). In the group of MGUS patients, expression levels of exosomal PRINS negatively correlated with albumin levels (r s = −0.440; P < 0.05) and positively with creatinine levels (r s = 0.512; P < 0.05), β 2 -microglobulin (r s = 0.611; P < 0.005), and lactate dehydrogenase (r s = 0,482; P < 0.05) (Table S1 ).
We did not observe dysregulation of PRINS expression levels between patients at different DS and ISS stages.
| LncRNA expression levels and cytogenetic aberrations association
Expression levels of PRINS were correlated with typical MM chromosomal aberrations, such as gain(1)(q21), del(13)(q14), del(17)(p13), t(4;14), and hyperdiploidy. Translocation t(4;14) was associated with lower exosomal PRINS levels (P < 0.05) in MM patients ( Figure S1 ).
No cytogenetics data were available for MGUS patients.
| Analysis of overall survival
LncRNA expression levels were studied as a possible indicator of This could lead to profiling of biologically relevant information for diagnosis as well as monitoring of treatment response and detection of minimal residual disease. For monoclonal gammopathies, liquid biopsies appear to be the way of the future. 2 The aim of this twophase biomarker study was to detect circulating lncRNA molecules in serum of MG patients and HD with possible diagnostic and prognostic potential.
In the first part of the study, only PRINS lncRNA was detected as differentially expressed in MM patients compared with HD (P < 0.05).
Based on results of profiling, literature and our own results, four lncRNA (PRINS, LINC-ROR, NEAT1, and UCA1) were selected for validation on a larger cohort of patients. However, in the validation phase, only two lncRNA, UCA1 and PRINS, were detected-and only PRINS remained statistically significant.
PRINS (psoriasis susceptibility-related RNA gene induced by stress) is an lncRNA that has been described in stress-induced psoriasis; its higher expression may increase susceptibility to this disease.
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The gene is located on chromosome 10 (10p12.1); the transcript is about 3.6-kb long. Increased expression of this lncRNA occurs with respect to proliferation and differentiation of keratinocytes and stress factors (UVB, viral infection, translation inhibition). In cells exposed to stress, PRINS has a protective role. Expression of this lncRNA was demonstrated in adrenocortical carcinoma. 15 However, expression of PRINS has not been described in hematological malignancies.
In the validation phase of the study, PRINS expression level was significantly different in the exosomal fraction of MM patients com- Based on our results, it seems that PRINS expression levels are not directly related to MM pathogenesis but may correlate with other processes in the body of the patients.
In MGUS patients, exosomal PRINS expression level negatively correlated with albumin levels, which reflects disease activity. Positive correlations with creatinine, β 2 -microglobulin and lactate dehydrogenase were observed indicating worse disease prognosis.
Moreover, there was no statistically significant association of PRINS expression and OS in MM patients. Exosomal PRINS expression levels were associated with translocation t (4;14) ; the presence of this translocation is a negative prognostic factor of MM. In our previous study, 10 we identified deregulated UCA1 in PCs of MM patients. We included UCA1 in the validation phase of the current study; however, it does not seem to be released into the serum of either group of patients or HD. In addition, in our previous study, we did not find PRINS to be differentially expressed between PCs of MM patients and HD. As we are not sure which tissue the circulating lncRNA are originating from, we did not expect similar results to our previous study.
There is only a limited amount of information available for circulating lncRNA in MM. To the best of our knowledge, three papers have been published so far. In the study of Isin et al, 7 they analyzed expres- peripheral blood serum in our study.
In the second study, the authors analyzed expression of only one circulating lncRNA-PCAT-1. They showed higher expression of circulating PCAT-1 in MM patients than in HD by qPCR. PCAT-1 was able to distinguish these two groups with 71.7% sensitivity and 93.8% specificity; its levels correlated with serum β 2 -microglobulin levels. 16 On contrary, our study used a more comprehensive approach of analysis of 84 lncRNA on a commercial platform and found deregulated expression of PRINS in exosomes of MM and MGUS patients.
The last study published recently showed elevated expression of lncRNA H19 in a cohort of MM patients by qRT-PCR. H19 was shown to correlate with MM staging. 17 However, this lncRNA was not expressed in our cohort.
| CONCLUSION
Our study indicates a potential of lncRNA as a possible minimally invasive marker of MM and MGUS. However, in order to use lncRNA molecules in the so-called liquid biopsies, further studies are needed.
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